Array Biopharma, Inc. (ARRY) Reports Q1 EPS Loss of $0.06, Sales Beat Expectations

Array Biopharma, Inc. (NASDAQ: ARRY) reported Q1 EPS of ($0.06), $0.13 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $22.1 million versus the consensus estimate of $17.38 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• ARRAY Technologies to Detail Balance-of-System Strategy and APA Long-Term Growth Opportunities at the APA Investor Technology Showcase Today
• Array Technologies holds investor showcase on balance-of-system strategy
• Advance Auto Parts (AAP) Tops Q2 EPS by 22c; lifrs profit guidance